5 unchanged sentences
Because many of our shares are held by brokers and other institutions on behalf of stockholders, we are unable to estimate the total number of beneficial holders represented by these record holders.
−Removed: Securities Authorized for Issuance Under Equity Compensation Plans
−Removed: We intend to file with the SEC a definitive Proxy Statement, which we refer to herein as the Proxy Statement, not later than 120 days after the close of the fiscal year ended December 31, 2020.
−Removed: The information required by this item relating to our equity compensation plans is incorporated herein by reference to the information contained under the section captioned “Equity Compensation Plan Information” of the Proxy Statement.
Stock Performance Graph
10 unchanged sentences
Nasdaq Biotechnology Total Return $ 100.00 $ 121.63 $ 110.85 $ 138.69 $ 175.33 $ 175.37
−Removed: SELECTED CONSOLIDATED FINANCIAL DATA
−Removed: The following selected consolidated financial data for each of the five years in the period ended December 31, 2020 are derived from our audited consolidated financial statements.
−Removed: The selected consolidated financial data set forth below should be read in conjunction with “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and the
−Removed: financial statements, and the related Notes, included elsewhere in this annual report on Form 10-K.
−Removed: Historical results are not necessarily indicative of future results.
−Removed: Selected Consolidated Financial Data
−Removed: (In thousands, except per share data)
−Removed: Year Ended December 31,
−Removed: 2020 2019 2018 (2) 2017 2016
−Removed: Statements of Operations Data:
−Removed: Revenues $ 492,853 $ 219,750 $ 74,908 $ 89,912 $ 47,159
−Removed: Operating costs and expenses (1) 1,321,291 1,159,181 889,581 590,000 471,746
−Removed: Loss from operations (828,438) (939,431) (814,673) (500,088) (424,587)
−Removed: Net loss $ (858,281) $ (886,116) $ (761,497) $ (490,874) $ (410,108)
−Removed: Net loss per common share — basic and diluted $ (7.46) $ (8.11) $ (7.57) $ (5.42) $ (4.79)
−Removed: Weighted-average common shares outstanding — basic
−Removed: and diluted 114,986 109,264 100,590 90,554 85,596
−Removed: (1) Stock-based compensation expenses included in operating costs and expenses $ 139,873 $ 174,841 $ 157,752 $ 92,819 $ 75,528
−Removed: (2) On January 1, 2018, we adopted the new revenue standard by applying the modified retrospective method to all contracts that were not completed as of January 1, 2018.
−Removed: Please read Note 2 to our consolidated financial statements included in Part II, Item 8, “Financial Statements and Supplementary Data,” in our annual report on Form 10-K for the fiscal year ended December 31, 2019 that was filed with the SEC on February 13, 2020 for further discussion of our adoption of the revenue standard.
−Removed: 2020 2019 2018 2017 2016 (1)
−Removed: Balance Sheet Data:
−Removed: Cash, cash equivalents and marketable securities $ 1,874,395 $ 1,536,162 $ 1,084,155 $ 1,704,537 $ 942,601
−Removed: Restricted investments 40,725 14,825 44,825 30,000 150,000
−Removed: Working capital 2,029,507 1,363,270 1,021,202 1,620,489 540,178
−Removed: Total assets 3,407,061 2,395,134 1,574,802 1,994,730 1,262,810
−Removed: Liability related to the sale of future royalties, net of current portion (Note 5) 1,058,225 — — — —
−Removed: Long-term debt 191,278 — 30,000 30,000 150,000
−Removed: Total stockholders’ equity 1,016,247 1,438,692 1,301,965 1,766,431 920,221
−Removed: (1) Excluding our investment in equity securities of Regulus Therapeutics, Inc.
+Added: Not applicable.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.